[
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Jonas Mandel",
    "section": "",
    "text": "Resume Publications\n\n\n\n About me\nAccomplished bioinformatics scientist with 14 years of experience in bioinformatics, omics data analysis, machine learning, and clinical biostatistics. Expert omics data analyst for RNAseq, scRNAseq, long-read sequencing, biomarker data analysis, GWAS. Expert R programmer with working knowledge of Python and proficiency in various bioinformatics & biostatistics methods & tools. Strong experience in scientific writing & communication for a variety of audiences (researchers, clinicians, investors). Focus areas: immuno-oncology, cardiology, neurology, rare diseases.\n\n\n Work Experience\n\nSenior Bioinformatics Scientist - Mnemo Therapeutics\n2021 - 2025, Paris\n\n\nDeveloped pipelines for detection of alternative splicing and cancer neoantigen prediction using RNAseq, scRNAseq, and long-read RNAseq (PacBio).\nLed integration of transcriptomics (&gt;20K RNAseq samples) and immunopeptidomics databases (&gt;1.5K samples) to generate target peptides libraries: &gt;1.2K putative targets, leading to 8 validated peptide targets.\nDesigned statistical analysis of neoantigen recurrence and peptide prioritization, instrumental for target mining strategy for vaccine and CAR-T development.\nImplemented long-read RNAseq pipeline for alternative splicing discovery & quantification based on IsoSeq3 & SQANTI.\nCoordinated cross-team efforts as work package lead for immunopeptidomics target mining; prepared scientific deliverables and presentations.\nParticipated in the design & setup of the bioinformatics work environment from scratch: github, AWS, Trello, …\nCompany-wide support to develop automated data analysis and reporting.\n\n\nBiomarker Biostatistician - Sanofi / Ividata\n2018 - 2021, Paris\n\n\nLed biomarker analyses in phase 2/3 trials (Sarilumab, Dupilumab, SAR440340) using RNAseq, SNP microarray, and proteomics (olink): SAP authoring & implementation with R, oversight of CROs, preparation of deliverables.\nBiomarker biostatistician and machine learning advisor in several R&D projects in oncology, cardiology, multiple sclerosis.\nDeveloped a shiny app for interactive reporting of omics biomarker data analysis.\nParticipated in the development of R trainings “Introduction to R” and “Graphs in R” for Sanofi statisticians & programmers.\n\n\nClinical Biostatistician - Sanofi / Ividata\n2016 - 2018, Paris\n\n\nGMA Study biostatistician for phase 3b clinical trial (Alirocumab, hypercholesterolemia): authoring SAP and TLFs specs, coordination with CRO & clinical team to prepare of deliverables (KRM, CSR), supervision & QC of CRO’s activities.\nLed the biostatistics & data analysis strategy for the Alirocumab publication program, overseeing data mining and post-hoc analyses of 14 pooled clinical trials to generate scientific insights and support publications in peer-reviewed journals.\n\n\nBiostatistician & Computational Genomics Scientist - Pharnext\n2012 - 2015, Paris\n\n\nLed design & implementation of a workflow for GWAS data imputation and analysis to discover disease-specific genomic alterations.\nDesigned & wrote SAP for Phase II/III clinical trials with adaptive designs, interim futility and power analysis, procedures for multiple endpoints. Meta-analysis of clinical trials.\nConducted biomarker statistical analysis for in-house clinical trials, including reportings and presentations for internal and external stakeholders (scientific & business).\n\n\nBiostatistics & Bioinformatics research engineer - Institut Curie / INSERM U900\n2009 - 2012, Paris\n\n\nPerformed omics statistical analyses (gene microarray, RNAseq, exome seq, SNP array) for various cancer research projects.\nDevelopment automated workflows for omics data analysis.\nParticipated to developing internal R programming training initiatives.\n\n\n\n\n Skills\n\nBiostatistics & Data Science\n\nStatistical modelling & inference: generalized linear model, mixed effects model, survival analysis, meta-analysis, PLS, principal component regression, interim analysis for clinical trials, conditional power analysis.\nMultivariate statistics: PCA, PLS, t-SNE, UMAP, multiple correspondence analysis, factor analysis.\nMachine learning: supervised classification & regression (LDA, SVM, Lasso / Elastic Net, boosting, bagging, random forests, XGBoost, …), unsupervised clustering (hierarchical clustering, k-means, DBSCAN, gaussian mixture models, …).\n\n\n\nOmics & Bioinformatics\n\nTranscriptomics (RNAseq, scRNAseq): alignment, normalization, differential analysis, splicing detection & quantification.\nLong-read sequencing (PacBio): transcript identification, isoform quantification, differential analysis.\nGenomics (WGS/WES): variant calling, CNV analysis, fusion gene detection.\nSNP microarrays & GWAS: imputation, association testing.\nPathway enrichment: GSA/GSEA.\n\n\n\nBioinformatics tools & workflows\n\nTools: STAR, Seurat, StringTie, Samtools, NetMHCpan, DeepTMHMM, PLINK, IsoSeq3, SQANTI, tappAS, BLAST.\nWorkflow development: Nextflow, Docker, Galaxy.\n\n\n\nProgramming & DataViz\nR (tidyverse, ggplot2, mlr3, tidymodels, RMarkdown, Shiny), Python (pandas, seaborn, scikit-learn, matplotlib)\n\n\nCollaboration & Project Management\nGit/GitHub, Trello, Teams, agile coordination, cross-functional communication\n\n\nLanguages\nEnglish (fluent), French (native), Spanish (good)\n\n\n\n Education\n\nMS in Bioinformatics and Modelling\nINSA Lyon, 2003 - 2008\n\n\nResearch internships\n\nCellular automaton modeling of the dynamics of epidemics – University of Amsterdam, 2008\nMathematical modelling of the effect of antibiotic dose on pneumococcus resistance to antibiotics – Institut Pasteur, 2007\n\n\n\nTrainings\nTime management (Cegos, 2024), Project management with Git & GitHub (ArData, 2022), Docker (Aneo, 2023), Machine learning & DataViz in Python (DataScientest, 2020).\n\n\n\n Interests\n\nTheater & acting\nHiking / running\nSociology, philosophy\nScience fiction litterature\n\n\n\n\n\n\nCombinational Drug Repurposing from Genetic Networks Applied to Alzheimer’s Disease. Nabirotchkin S, Bouaziz J, Glibert F, Mandel J, Foucquier J, Hajj R, Callizot N, Cholet N, Guedj M, Cohen D. J Alzheimers Dis. 2022;88(4):1585-1603. doi: 10.3233/JAD-220120.\nTriglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. Vallejo-Vaz AJ, Leiter LA, Del Prato S, Taskinen MR, Müller-Wieland D, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Ray KK. Eur J Prev Cardiol. 2020 Oct;27(15):1663-1674. doi: 10.1177/2047487320905185.\nAlirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Ray KK, Del Prato S, Müller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, Letierce A, Mandel J, Samuel R, Bujas-Bobanovic M, Leiter LA. Cardiovasc Diabetol. 2019 Nov 9;18(1):149. doi: 10.1186/s12933-019-0951-9.\nAlirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH. Diabet Med. 2018;35:1742-1751. doi: 10.1111/dme.13817.\nEfficacy and Safety of Alirocumab Among Individuals with Diabetes Mellitus and Atherosclerotic Cardiovascular Disease in the Odyssey Phase 3 Trials. Ganda OP, Plutzky J, Sanganalmath SK, Bujas-Bobanovic M, Koren A, Mandel J, Letierce A, Leiter LA. Diabetes Obes Metab. 2018 Oct;20(10):2389-2398. doi: 10.1111/dom.13384.\nEfficacy and Safety of Lipid Lowering by Alirocumab in Chronic Kidney Disease. Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, Louie MJ, Koren A, Letierce A, Mandel J, Banach M. Kidney Int. 2018 Mar 8. pii: S0085-2538(18)30055-3. doi: 10.1016/j.kint.2017.12.011.\nEfficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH. Am J Cardiol. 2018 Apr 15;121(8):940-948. doi: 10.1016/j.amjcard.2017.12.040.\nNo Evidence of Neurocognitive Adverse Events Associated with Alirocumab Treatment in 3340 Patients from 14 Randomized Phase 2 and 3 Controlled Trials: A Meta-Analysis of Individual Patient Data. Harvey PD, Sabbagh MN, Harrison JE, Ginsberg HN, Chapman MJ, Manvelian G, Moryusef A, Mandel J, Farnier M. Eur Heart J. 2018 Feb 1;39(5):374-381. doi: 10.1093/eurheartj/ehx661.\nEfficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Leiter LA, Cariou B, Müller-Wieland D, Colhoun HM, Del Prato S, Tinahones FJ, Ray KK, Bujas-Bobanovic M, Domenger C, Mandel J, Samuel R, Henry RR. Diabetes Obes Metab. 2017 Dec;19(12):1781-1792. doi: 10.1111/dom.13114.\nWhole-genome profiling helps to classify phyllodes tumours of the breast. Laé M, La Rosa P, Mandel J, Reyal F, Hupé P, Terrier P, Couturier J. J Clin Pathol. 2016 Dec; 69(12):1081-1087. doi: 10.1136/jclinpath-2016-203684.\nA Multi-Marker Genetic Association Test Based on the Rasch Model Applied to Alzheimer’s Disease. Wang W, Mandel J, Bouaziz J, Commenges D, Nabirotchkine S, Chumakov I, Cohen D, Guedj M; Alzheimer’s Disease Neuroimaging Initiative. PLoS One. 2015 Sep 17;10(9). doi: 10.1371/journal.pone.0138223.\nA meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment. Mandel J, Bertrand V, Lehert P, Attarian S, Magy L, Micallef J, Chumakov I, Scart-Grès C, Guedj M, Cohen D. Orphanet J Rare Dis. 2015 Jun 13;10:74. doi: 10.1186/s13023-015-0293-y.\nAn exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Attarian S, Vallat JM, Magy L, Funalot B, Gonnaud PM, Lacour A, Péréon Y, Dubourg O, Pouget J, Micallef J, Franques J, Lefebvre MN, Ghorab K, Al-Moussawi M, Tiffreau V, Preudhomme M, Magot A, Leclair-Visonneau L, Stojkovic T, Bossi L, Lehert P, Gilbert W, Bertrand V, Mandel J, Milet A, Hajj R, Boudiaf L, Scart-Grès C, Nabirotchkin S, Guedj M, Chumakov I, Cohen D. Orphanet J Rare Dis. 2014, Dec 18;9(1):199. doi: 10.1186/s13023-014-0199-0.\nPolytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Attarian S, Vallat JM, Magy L, Funalot B, Gonnaud PM, Lacour A, Péréon Y, Dubourg O, Pouget J, Micallef J, Franques J, Lefebvre MN, Ghorab K, Al-Moussawi M, Tiffreau V, Preudhomme M, Magot A, Leclair-Visonneau L, Stojkovic T, Bossi L, Lehert P, Gilbert W, Bertrand V, Mandel J, Milet A, Hajj R, Boudiaf L, Scart-Grès C, Nabirotchkin S, Guedj M, Chumakov I, Cohen D. Orphanet J Rare Dis 2014, Dec 18;9(1):199. doi: 10.1186/s13023-014-0201-x.\nAntibiotic dose impact on resistance selection in the community: a mathematical model of beta-lactams and Streptococcus pneumoniae dynamics. Opatowski L, Mandel J, Varon E, Boëlle PY, Temime L, Guillemot D. Antimicrob Agents Chemother 2010, Jun; 54(6):2330-7. doi: 10.1128/aac.00331-09."
  }
]